Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

Januvia (sitagliptin) is a medication for type 2 diabetes. Along with diet and exercise, it can help lower blood sugar levels. Medicare Part D will generally cover prescription drugs, like Januvia.

Merck’s full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

On its last weekday in power, the Biden Administration has chosen the next batch of drugs up for price negotiation in ...

Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted profits topping expectations.

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.

The S&P 500 added 0.7% on Tuesday, Feb. 4, as investors evaluated developments on U.S. tariffs, labor market data, and the latest earnings news.

Q4 2024 Earnings Call Transcript February 4, 2025 Merck & Co., Inc. misses on earnings expectations. Reported EPS is $1.72 ...

January is a big time for drugmakers to hike prices. This year saw higher prices for 575 medications so far, including Ozempic, drugs for HIV, cancer and many others.